Compounds · Other compounds · continued

Research-use-only status: what it means legally and practically — a second dataset posts 121–126

Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

dr_bhattacharyaTL3Physician21 Mar 2025#121

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

0 likes 16mo

t.duarteTL2 Moderator22 Mar 2025#122

Worth separating two things that post #118 runs together.

Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness.

2 likes 16mo

e.ferreiraTL3Regular23 Mar 2025#123

This follows post #120 rather than contradicting it.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

8 likes 16mo

h.falkTL2 Moderator24 Mar 2025 · edited#124

t.karlsen, post #107: Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

20 likes in reply to #107 16mo

r.aldana_pharmdTL4Pharmacist25 Mar 2025#125

m.ibarra, post #24: Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning. Go to post

post #124 answers the question as asked. The question underneath it is different.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

0 likes in reply to #24 16mo

s.okaforTL2 Moderator26 Mar 2025#126

On post #122 — agreed on the reasoning, with one qualification.

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

0 likes 16mo

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Other compounds category Compounds › Other compounds research use only custom synthesis needs a source Pinned Wiki Closed Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+8	12	51k	7mo
Coming back to: When "no data" is the complete and final answer Compounds › Other compounds research use only needs a source custom synthesis When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+77	82	12k	11mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…	+100	108	1.3k	8mo
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+72	81	44k	1d
AOD-9604 and the fragment hypothesis, revisited Compounds › Other compounds mislabelling research use only custom synthesis needs a source Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…	+40	44	2.8k	6mo

Related topics — sharing the tags research use only, mislabelling, needs a source

Topic	Participants	Replies	Views	Activity
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA EMA compounding research use only Closed On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…	+76	82	52k	11mo
Labelling requirements for research chemicals — the long version Sourcing › Regulatory MHRA research use only compounding personal import Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…		2	1.8k	2mo
Follow-up: Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis CJC-1295 ipamorelin tesamorelin needs a source On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…	+20	24	18k	4mo
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…	+86	97	62k	8mo
Documenting a payment dispute without naming and shaming — the long version Sourcing › Payments documentation quality payments research use only Posting this under the heading it deserves: Documenting a payment dispute without naming and shaming — the long version Everything below is what sits behind that. I would like to talk about documentation…		2	32k	1mo